Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Bevacizumab also may stop the
growth of breast cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such
as doxorubicin hydrochloride liposome, work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab
together with doxorubicin hydrochloride liposome may kill more tumor cells.
PURPOSE: This phase II trial is studying the side effects and how well giving bevacizumab
together with doxorubicin hydrochloride liposome works in treating women with locally
recurrent or metastatic breast cancer.